CLINICAL STUDIES ON AB-206 IN RESPIRATORY INFECTIOUS DISEASES

• Published in: CHEMOTHERAPY Vol. 26; no. Supplement4; pp. 295 - 302
• Main Authors: TSUJIMOTO, TAKEHIRO, YAMAGUCHI, SAKIMORI, TAKAHASHI, HISAO, OCHI, TADAO, KONISHIIKE, JOICHI, YAMAZAKI, MASAYASU, ARAMI, SABURO, TSUBURA, EIRO, KAWANO, MICHIAKI, YAMAMURA, YUICHI, HIRAO, FUMIO, OGURA, TAKESHI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 25.09.1978
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.26.Supplement4_295

Clinical studies on AB-206, a new broad antibacterial spectrum quinoline derivative, were carried out and the following results were obtained: 43 patients with respiratory tract infectious diseases were treated with AB-206 at 1g 4 th a day by oral administration; 3 cases of acute bronchitis, 8 of pneumonia, 2 of lung abscess, one of panbronchiolitis, 21 of chronic bronchitis and 9 cases of bronchiectasis. Out of 10 cases of pneumonia and lung abscess, clinical excellent and good response was observed in 70% and 4 cases out of 9 acute exacerbated chronic respiratory tract infectious disease revealed good result. Good correlation was also observed between these clinical results and bacteriological effect on the organism detected from sputum specimens. In this respect, these effects are favorably comparable with some reliable studies reported previously. In 20 cases of chronic course type of infectious chronic bronchitis and bronchiectasis, good response was observed in 15.0%. This poor effect will be due to low degree of infectious findings, advanced and prolonged chronic bronchial inflammation. As side effect, each one case complained of nausea, appetiteloss and epigastrial discomfort in slight degree and slight elevation of GOT was observed in 2 cases.